Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
April 30 2020 - 4:15PM
Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company
pioneering treatments for autoimmune and severe inflammatory
diseases, today announced the election of Rachelle Jacques to its
Board of Directors. As a veteran of the biotechnology and
pharmaceutical industries, Ms. Jacques has held various leadership
roles of increasing responsibility throughout her career. She
currently serves as the Chief Executive Officer at Enzyvant
Therapeutics, Inc., a biopharmaceutical company focused on
developing therapies for patients with rare diseases.
“We are pleased to welcome Rachelle to our Board of Directors,”
commented Bing Yao, Ph.D., Chief Executive Officer at Viela Bio.
“Her expertise in launching and marketing important therapeutics
for rare diseases will help further strengthen our capabilities as
we prepare for the potential commercialization of our lead asset,
inebilizumab, for the treatment of patients with neuromyelitis
optica spectrum disorder.”
Prior to joining Enzyvant, Ms. Jacques served as the Senior Vice
President and Global Complement Franchise Head at Alexion
Pharmaceuticals, Inc. Previously, Ms. Jacques was Vice President of
U.S. Hematology Marketing at Shire plc, which acquired Baxalta Inc.
(“Baxalta”) in 2016 and served as Vice President of Business
Operations at Baxalta after its spinoff from Baxter International
Inc. (“Baxter”) in 2015. Also at Baxter, Ms. Jacques held multiple
leadership positions, including Vice President of Finance, U.S.
BioScience Business.
Earlier in her career, Ms. Jacques served in various roles of
increasing responsibility at Dow Corning Corporation, including
U.S. and international operational management roles.
Ms. Jacques currently serves on the Board of Directors of Corbus
Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP). She received a B.A.
degree in business administration from Alma College.
About Viela Bio
Viela Bio, headquartered in Gaithersburg, Maryland, is a
clinical-stage biotechnology company dedicated to the discovery,
development and commercialization of novel treatments for
autoimmune and severe inflammatory diseases. For more information,
please visit www.vielabio.com.
Forward Looking Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical
facts, contained in this press release, including statements
regarding our strategy, future operations, prospects, plans,
objectives of management, and the timing and progress of clinical
development of our product candidates, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue” or the negative of these terms or other
comparable terminology, which are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. We may not
actually achieve the plans, intentions or expectations disclosed in
our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we
make. Various factors may cause differences between our
expectations and actual results as discussed in greater detail in
our filings with the Securities and Exchange Commission (SEC),
including without limitation, the risks and uncertainties described
in the section entitled “Risk Factors” in our Annual Report on Form
10-K for the year ended December 31, 2019, which was filed with the
SEC on March 25, 2020 or in subsequent filings that we make with
the SEC. We do not assume any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Source: Viela Bio
Contacts:
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Amy Bonanno
914-450-0349
abonanno@soleburytrout.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From May 2024 to Jun 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2023 to Jun 2024